Klaria Pharma concludes rights issue subscription period
Klaria Pharma Holding AB has set November 6, 2026, as the final deadline for shareholders to participate in its rights issue, aiming to raise approximately SEK 147.6 million.
Klaria Pharma Holding AB is reaching the end of its subscription period for a rights issue aimed at raising up to SEK 147.6 million. The company confirmed that November 6, 2026, serves as the final day for investors to exercise their subscription rights.
The company advised shareholders that intermediary financial institutions and nominees may enforce earlier internal deadlines for processing applications. Investors utilizing the services of the issuing agent, Vator Securities, must finalize their submissions by 15:00 CET today.
This capital raise follows recent efforts by the pharmaceutical firm to stabilize its financial position. The proceeds from the rights issue are intended to support the company's ongoing research and operational activities.